Leading the Way in Life Science Technologies

GEN Exclusives

More »


More »
October 01, 2009 (Vol. 29, No. 17)

Biosimilar Market Fails to Meet Projections

End-User Resistance, Legislative Hurdles, and Limited Competition Have Skewed Predictions

  • Click Image To Enlarge +
    World market potential for biosimilars (market share 2009)

    Even if legislative hurdles are worked out, the U.S. market for biosimilars may not be the multibillion dollar market that many analysts have projected. But that doesn’t mean there won’t be robust competition. Long-term, generic competition will still change the way biopharmaceuticals are sold in the United States.

    The $40 billion biopharmaceutical market including vaccines, most new cancer agents, and arthritis and psoriasis drugs is the fastest growing segment of the pharmaceutical industry. Some of the most expensive drugs in the world are biologics.

    Biopharmaceuticals account for about 250 of the more than 10,000 drugs on the market, but represent a disproportionate share of the nation’s healthcare spending, costing Medicare Part B more than $12 billion in 2008. Since the generic industry has done much to reduce pharmaceutical costs in the past 25 years, it’s no wonder that many are looking to generic competition to reduce the costs of biologics. 

    The term biosimilars is used since, unlike generic pharmaceuticals, there are no truly exact biologic replica due to the complex process of creating biopharmaceuticals, so generic products are either similar in nature or in some cases improvements over the original. There currently is no pathway for these products in the U.S. market, but recent House and Senate committee approvals portend some kind of mechanism for U.S. approvals by next year.

    At the time of writing, Congress is still deciding whether the exclusivity period for biological products will be set at 5 or 12 years. Biosimilars likely to enter the U.S. are first-generation products such as human growth hormone (HGH) and insulin, as well as second-generation products such as protein and recombinant DNA treatments.

  • Market Size

    As of 2008, Kalorama Information estimates a $60 million biosimilar market in the European Union. A variety of factors have contributed to this diminished market size, including end-user resistance. Also, rather than the scores of entrants in this marketplace that were expected, competition is limited and typically against branded drugs rather than other generic drugs. The production and distribution competency required for the biosimilar process severely limits the number of players. 

    The robust competition among a few experienced and strongly funded competitors will create a U.S. market for biosimilar drugs that Kalorama Information estimates could reach $30 million by 2013.  As products develop, the U.S. market will build over the next decade. We expect the same pattern that occurred in the generic industry in the ’80s. Slower than anticipated growth with some resistance at first, then a flourishing market. Our U.S. market figure may surprise some due to the generous predictions made when biogeneric approval was first discussed.

    Don’t tell a product manager at an established branded biologic that U.S. biosimilars won’t be a significant headache. The total market may be smaller than previously projected, but those products that face biosimilar competition will need to change their business plans dramatically.

    This does not mean there won’t be competitive activity, just that the field of play will be narrower than previously thought. Competition will open up between producers of biosimilars and producers of branded biopharmaceuticals if, as looks likely, Congress approves these drugs in the U.S.

    It’s a small but experienced group that will lead the competition in the U.S. Some of the leaders emerging in the market are Cangene, Biocon, Sandoz, TEVA, and Dr. Reddy’s. Having successfully marketed biogeneric products in Europe and Asia, these companies will come prepared to the new market. Among biological products being challenged is Amgen’s chemotherapy drug Neupogen, which stimulates production of white blood cells, and Genentech’s Rituxan, a protein used in the treatment of rheumatoid arthritis and non-Hodgkin’s lymphoma.

    Currently, the world market for biosimilars is fueled primarily by the demand for bioequivalent versions of erythropoietin and G-CSF. Sales for these products were estimated at $62 million in 2008. This includes sales for products in Europe and throughout the world where lenient biosimilar laws exist. 

    Insulin is a long-time favorite for biosimilar production with a relatively simple manufacturing method to follow. However, sales continue to be minimal in contrast to the total insulin market. 

    Another focus for biosimilar production in the United States and key markets in Europe is HGH. Sales, however, have failed to show the significant gains that manufacturers expected. Sales for bioequivalent HGH have been estimated at $15 million globally for 2008.

Posted 10/1/2009 by GEN Managing Editor

The $94 billion number given in the special report of March 4 by Debby Strickland was the entire biologics market, the number given by Bruce Carlson in this article represents only a segment of the market. As Bruce states in this article projections for this market have been overly optimistic in the past. I suspect some of the discrepancy is also related to the different market analysis firms preparing the projections.

Posted 10/1/2009 by Inconsistency in Market Estimates

On Mar 4, 2009, GEN had an article that stated the worldwide biologics market in 2007 was $94 billion and growing rapidly. Now, we hear it was $40 billion in 2008. The market shrank 57% in one year???? What numbers should we believe?


Related content